Clinically-relevant consecutive treatment with isoproterenol and adenosine protects the failing heart against ischaemia and reperfusion

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Khaliulin, Igor ^a   Halestrap, Andrew P ^a   Bryant, Simon M ^a   Dudley, Declan J ^a   James, Andrew F ^a   Suleiman, M Saadeh ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adenosine; Cardioprotection; Heart failure; Ischaemia reperfusion; Isoproterenol; Mitochondria permeability transition pore

Indexed keywords

ADENOSINE; CYCLOSPORIN A; GLYCOGEN; ISOPRENALINE; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLYCOGEN ANALYSIS; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; LEFT CORONARY ARTERY; MALE; MITOCHONDRIAL PERMEABILITY; NONHUMAN; RAT; REPERFUSION INJURY; ANIMAL; HEART FAILURE; HEART MUSCLE; HEMODYNAMICS; IN VITRO STUDY; METABOLISM; WISTAR RAT;

ADENOSINE; ANIMALS; GLYCOGEN; HEART FAILURE; HEMODYNAMICS; IN VITRO TECHNIQUES; ISOPROTERENOL; MALE; MYOCARDIUM; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 84901823161     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-139     Document Type: Article

References (39)

1. Depre C, Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res 2000, 45:538-548. 10.1016/S0008-6363(99)00266-7, 10728375.
2. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011, 17:1391-1401. 10.1038/nm.2507, 3886192, 22064429.
3. Khaliulin I, Clarke SJ, Lin H, Parker JE, Suleiman MS, Halestrap AP. Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol 2007, 581:1147-1161. 10.1113/jphysiol.2007.130369, 1976396, 17395631.
4. Khaliulin I, Parker JE, Halestrap AP. Consecutive pharmacological activation of PKA and PKC mimics the potent cardioprotection of temperature preconditioning. Cardiovasc Res 2010, 88:324-333. 10.1093/cvr/cvq190, 2952531, 20558443.
5. Khaliulin I, Halestrap AP, Suleiman MS. Temperature preconditioning is optimal at 26°C and confers additional protection to hypothermic cardioplegic ischemic arrest. Exp Biol Med 2011, 236:736-745.
6. Gilmore K, Nanyanzi C. Pharmacology of vasopressors and inotropes. Update Aneasthesia 1999, 10:1-2.
7. Mentzer RM, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD, Wellons HA, Barker ML, Lasley RD. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg 1999, 229:643-649. discussion 649-650, 10.1097/00000658-199905000-00006, 1420808, 10235522.
8. Liu R, Xing J, Miao N, Li W, Liu W, Lai Y-Q, Luo Y, Ji B. The myocardial protective effect of adenosine as an adjunct to intermittent blood cardioplegia during open heart surgery. Eur J Cardiothorac Surg 2009, 36:1018-1023. 10.1016/j.ejcts.2009.06.033, 19683936.
9. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007, 1767:1007-1031. 10.1016/j.bbabio.2007.05.008, 2212780, 17631856.
10. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005, 111:194-197. 10.1161/01.CIR.0000151290.04952.3B, 15642769.
11. Wang L, Oka N, Tropak M, Callahan J, Lee J, Wilson G, Redington A, Caldarone CA. Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 2008, 136:335-342. 10.1016/j.jtcvs.2007.12.055, 18692639.
12. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol 2010, 105:151-154. 10.1007/s00395-009-0080-9, 20066536.
13. Liu L, Zhu J, Brink PR, Glass PSA, Rebecchi MJ. Age-associated differences in the inhibition of mitochondrial permeability transition pore opening by cyclosporine A. Acta Anaesthesiol Scand 2011, 55:622-630. 10.1111/j.1399-6576.2011.02421.x, 21827445.
14. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 2010, 3:35-38. 10.1242/dmm.003855, 20075380.
15. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 1979, 44:503-512. 10.1161/01.RES.44.4.503, 428047.
16. Passonneau JV, Lauderdale VR. A comparison of three methods of glycogen measurement in tissues. Anal Biochem 1974, 60:405-412. 10.1016/0003-2697(74)90248-6, 4844560.
17. Bergmeyer H-U, Bernt E. Lactate dehydrogenase. Methods of Enzymatic Analysis 1963, 574-579. London: Academic, Bergmeyer H-U.
18. Pasdois P, Beauvoit B, Costa ADT, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Santos PD. Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: Implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J Mol Cell Cardiol 2007, 42:631-642. 10.1016/j.yjmcc.2006.12.014, 17306295.
19. Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: Fixing a hole. Cardiovasc Res 2006, 70:191-199. 10.1016/j.cardiores.2006.01.016, 16497286.
20. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 2009, 104:181-188. 10.1007/s00395-009-0004-8, 2671061, 19242640.
21. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003, 93:292-301. 10.1161/01.RES.0000087542.26971.D4, 12933700.
22. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003, 549:513-524. 10.1113/jphysiol.2003.034231, 2342939, 12692185.
23. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993, 25:1461-1469. 10.1006/jmcc.1993.1162, 7512654.
24. Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 2002, 277:34793-34799. 10.1074/jbc.M202191200, 12095984.
25. Onishi A, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Direct evidence for inhibition of mitochondrial permeability transition pore opening by sevoflurane preconditioning in cardiomyocytes: Comparison with cyclosporine A. Eur J Pharmacol 2012, 675:40-46. 10.1016/j.ejphar.2011.11.040, 22166375.
26. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 2007, 42:150-158. 10.1016/j.yjmcc.2006.09.013, 2700715, 17070837.
27. Weinbrenner C, Liu GS, Downey JM, Cohen MV. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc Res 1998, 38:676-684. 10.1016/S0008-6363(98)00064-9, 9747435.
28. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? : A controversy resolved. Circ Res 1996, 78:482-491. 10.1161/01.RES.78.3.482, 8593707.
29. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009, 1787:1402-1415. 10.1016/j.bbabio.2008.12.017, 19168026.
30. Pasdois P, Parker JE, Halestrap AP. Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc 2013, 2:e005645.
31. Pastorino J, Hoek J. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008, 40:171-182. 10.1007/s10863-008-9148-8, 2662512, 18683036.
32. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, Sollott SJ, Forte M, Bernardi P, Rasola A. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 2008, 3:e1852. 10.1371/journal.pone.0001852, 2267038, 18350175.
33. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-458. 10.1124/pr.107.06002, 18048761.
34. Balakumar P, Singh H, Singh M, Anand-Srivastava MB. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res 2009, 60:18-23. 10.1016/j.phrs.2009.03.002, 19427581.
35. Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS. Tolerance of the hypertrophic heart to ischemia: Studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation 1990, 81:1644-1653. 10.1161/01.CIR.81.5.1644, 2139593.
36. Andersen A, Povlsen JA, Bøtker HE, Nielsen-Kudsk JE. Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning. Eur J Heart Fail 2013, 15:1208-1214. 10.1093/eurjhf/hft105, 23818649.
37. Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258. 10.1152/physrev.00015.2009, 20086077.
38. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129. 10.1152/physrev.00006.2004, 15987803.
39. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation - A novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813, 2011:1333-1350.